Apr, 2019

U.S.A.
News / Corporate
Astellas Statement on U.S. Department of Justice Settlement Related to Patient Co-Pay Assistance Foundations
Astellas and the U.S. Department of Justice (DOJ) have reached an agreement to resolve all claims raised by the government in its investigation regarding Astellas’ past donations to U.S. 501(c)(3) patient co-pay assistance foundations. The foundations are independent charitable organizations that provide financial assistance to patients who cannot afford the co-pay amounts for their medications...
Read More
U.S.A.
News / Corporate
Astellas Announces Key Senior Leadership Promotions and New Hire in Medical and Development Organization
Astellas is pleased to announce two recent senior-level promotions and one new hire within its Medical and Development (M&D) organization. Steven Benner, M.D., was promoted to president and Head...
Read More
U.S.A.
News / Corporate
Phase 3 ADMIRAL Trial Data Show XOSPATA® (gilteritinib) Significantly Prolongs Overall Survival in Adult Patients with FLT3 Mutation-Positive Relapsed/Refractory Acute Myeloid Leukemia Compared with Salvage Chemotherapy
Astellas Pharma Inc. (TSE: 4503) (President and CEO: Kenji Yasukawa, Ph.D. "Astellas") today announced results from the Phase 3 ADMIRAL clinical trial comparing XOSPATA® (gilteritinib) to salvage...
Read More

Mar, 2019

U.S.A.
News / Corporate
Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
Seattle Genetics, Inc. (Nasdaq: SGEN) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced positive topline results from the first cohort of...
Read More
U.S.A.
News / Corporate
Astellas Launches PROGRAF® Granules (tacrolimus for oral suspension) in the U.S. for Pediatric Liver, Heart, and Kidney Transplant Patients
Astellas announced today that PROGRAF® Granules (tacrolimus for oral suspension) is now available for prescription in the United States. PROGRAF is used in combination with other...
Read More